Encore Vision Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$456M
Encore Vision General Information
Description
Developer of ophthalmic therapeutics to treat the eye condition presbyopia. The company provides an eye drop treatment designed to reduce eye lens stiffness and make the lens less viscous to restore flexibility, allowing the lens to thicken in the center during an attempt to focus on nearby objects, enabling patients to recover sight.
Contact Information
Website
www.encorevisioninc.comCorporate Office
- 1120 South Freeway
- Suite 118
- Fort Worth, TX 76104
- United States
Corporate Office
- 1120 South Freeway
- Suite 118
- Fort Worth, TX 76104
- United States
Encore Vision Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 20-Jan-2017 | $456M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series C) | 12-May-2016 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B1) | 09-Feb-2015 | Completed | Product Development | |||
| 4. Later Stage VC (Series B) | 16-Sep-2014 | Completed | Product Development | |||
| 3. Grant | 01-Jan-2013 | Completed | Product Development | |||
| 2. Accelerator/Incubator | $1.92M | Completed | Startup | |||
| 1. Early Stage VC (Series A) | 10-Jun-2010 | $1.92M | $1.92M | Completed | Startup |
Encore Vision Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | 38,000,000 | $0.001000 | 8% | $0.18 | $0.18 | 1x | $0.18 | 33.14% |
| Series A | 24,828,813 | $0.001000 | 8% | $0.08 | $0.08 | 1x | $0.08 | 21.66% |
Encore Vision Patents
Encore Vision Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018055572-A1 | Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products | Inactive | 23-Sep-2016 | ||
| US-20220096434-A1 | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations | Inactive | 24-Sep-2015 | ||
| WO-2017053646-A1 | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations | Inactive | 24-Sep-2015 | ||
| AU-2015227307-A1 | Lipoic acid choline ester compositions and methods of use | Inactive | 03-Mar-2014 | ||
| WO-2015134510-A1 | Lipoic acid choline ester compositions and methods of use | Inactive | 03-Mar-2014 | A61K9/08 |
Encore Vision Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bios Partners | Venture Capital | Minority | ||
| GrowCo Capital | Venture Capital | Minority | ||
| Sea Purity Investments | Family Office | Minority | ||
| Steelhead Capital Management | Family Office | Minority | ||
| TechFW | Accelerator/Incubator |
Encore Vision Acquisitions (1)
Encore Vision’s most recent deal was a Merger/Acquisition with Evermind (Electronic Equipment and Instruments). The deal was made on 01-Nov-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Evermind (Electronic Equipment and Instruments) | 01-Nov-2016 | Merger/Acquisition | Electronic Equipment and Instruments |
Encore Vision FAQs
-
When was Encore Vision founded?
Encore Vision was founded in 2007.
-
Where is Encore Vision headquartered?
Encore Vision is headquartered in Fort Worth, TX.
-
What industry is Encore Vision in?
Encore Vision’s primary industry is Pharmaceuticals.
-
Is Encore Vision a private or public company?
Encore Vision is a Private company.
-
What is the current valuation of Encore Vision?
The current valuation of Encore Vision is .
-
What is Encore Vision’s current revenue?
The current revenue for Encore Vision is .
-
How much funding has Encore Vision raised over time?
Encore Vision has raised $14.2M.
-
Who are Encore Vision’s investors?
Bios Partners, GrowCo Capital, Sea Purity Investments, Steelhead Capital Management, and TechFW are 5 of 6 investors who have invested in Encore Vision.
-
When was Encore Vision acquired?
Encore Vision was acquired on 20-Jan-2017.
-
Who acquired Encore Vision?
Encore Vision was acquired by Novartis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process